270 related articles for article (PubMed ID: 10534255)
1. Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E epsilon4 status.
Graves AB; Bowen JD; Rajaram L; McCormick WC; McCurry SM; Schellenberg GD; Larson EB
Neurology; 1999 Oct; 53(7):1480-7. PubMed ID: 10534255
[TBL] [Abstract][Full Text] [Related]
2. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study.
Peila R; White LR; Petrovich H; Masaki K; Ross GW; Havlik RJ; Launer LJ
Stroke; 2001 Dec; 32(12):2882-9. PubMed ID: 11739991
[TBL] [Abstract][Full Text] [Related]
3. Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population.
Qiu C; Winblad B; Fratiglioni L
Neurol Res; 2006 Sep; 28(6):650-6. PubMed ID: 16945218
[TBL] [Abstract][Full Text] [Related]
4. Olfactory identification and apolipoprotein E epsilon 4 allele in mild cognitive impairment.
Wang QS; Tian L; Huang YL; Qin S; He LQ; Zhou JN
Brain Res; 2002 Sep; 951(1):77-81. PubMed ID: 12231459
[TBL] [Abstract][Full Text] [Related]
5. APOE-epsilon4 is associated with memory decline in cognitively impaired elderly.
Dik MG; Jonker C; Bouter LM; Geerlings MI; van Kamp GJ; Deeg DJ
Neurology; 2000 Apr; 54(7):1492-7. PubMed ID: 10751265
[TBL] [Abstract][Full Text] [Related]
6. Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly.
Dik MG; Jonker C; Comijs HC; Bouter LM; Twisk JW; van Kamp GJ; Deeg DJ
Neurology; 2001 Dec; 57(12):2217-22. PubMed ID: 11756600
[TBL] [Abstract][Full Text] [Related]
7. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
[TBL] [Abstract][Full Text] [Related]
8. APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging.
Bunce D; Fratiglioni L; Small BJ; Winblad B; Bäckman L
Neurology; 2004 Sep; 63(5):816-21. PubMed ID: 15365129
[TBL] [Abstract][Full Text] [Related]
9. APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment.
Ballard CG; Morris CM; Rao H; O'Brien JT; Barber R; Stephens S; Rowan E; Gibson A; Kalaria RN; Kenny RA
Neurology; 2004 Oct; 63(8):1399-402. PubMed ID: 15505155
[TBL] [Abstract][Full Text] [Related]
10. The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging.
Bretsky P; Guralnik JM; Launer L; Albert M; Seeman TE;
Neurology; 2003 Apr; 60(7):1077-81. PubMed ID: 12682309
[TBL] [Abstract][Full Text] [Related]
11. Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: A population-based study.
Dik MG; Deeg DJ; Bouter LM; Corder EH; Kok A; Jonker C
Stroke; 2000 Oct; 31(10):2431-6. PubMed ID: 11022076
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E epsilon4 and change in cognitive functioning in community-dwelling older adults.
Swan GE; Lessov-Schlaggar CN; Carmelli D; Schellenberg GD; La Rue A
J Geriatr Psychiatry Neurol; 2005 Dec; 18(4):196-201. PubMed ID: 16306239
[TBL] [Abstract][Full Text] [Related]
13. Association between serum beta-carotene levels and decline of cognitive function in high-functioning older persons with or without apolipoprotein E 4 alleles: MacArthur studies of successful aging.
Hu P; Bretsky P; Crimmins EM; Guralnik JM; Reuben DB; Seeman TE
J Gerontol A Biol Sci Med Sci; 2006 Jun; 61(6):616-20. PubMed ID: 16799145
[TBL] [Abstract][Full Text] [Related]
14. The joint effect of apolipoprotein E epsilon4 and MRI findings on lower-extremity function and decline in cognitive function.
Carmelli D; DeCarli C; Swan GE; Kelly-Hayes M; Wolf PA; Reed T; Guralnik JM
J Gerontol A Biol Sci Med Sci; 2000 Feb; 55(2):M103-9. PubMed ID: 10737693
[TBL] [Abstract][Full Text] [Related]
15. Smell identification test as an indicator for cognitive impairment in Alzheimer's disease.
Suzuki Y; Yamamoto S; Umegaki H; Onishi J; Mogi N; Fujishiro H; Iguchi A
Int J Geriatr Psychiatry; 2004 Aug; 19(8):727-33. PubMed ID: 15290695
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E ε4 and later-life decline in cognitive function and grip strength.
Batterham PJ; Bunce D; Cherbuin N; Christensen H
Am J Geriatr Psychiatry; 2013 Oct; 21(10):1010-9. PubMed ID: 23567378
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population.
Yip AG; Brayne C; Easton D; Rubinsztein DC;
J Med Genet; 2002 Sep; 39(9):639-43. PubMed ID: 12205106
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of the effect of apolipoprotein E epsilon4 and education on cognitive performance in elderly subjects: the PAQUID study.
Winnock M; Letenneur L; Jacqmin-Gadda H; Dallongeville J; Amouyel P; Dartigues JF
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):794-7. PubMed ID: 12023428
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.
Bennett DA; Wilson RS; Schneider JA; Evans DA; Aggarwal NT; Arnold SE; Cochran EJ; Berry-Kravis E; Bienias JL
Neurology; 2003 Jan; 60(2):246-52. PubMed ID: 12552039
[TBL] [Abstract][Full Text] [Related]
20. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
Klages JD; Fisk JD; Rockwood K
Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
